The Pharmacodynamics Research Of The Compound Qing Gan Pai Du Yin Anti-HBV And Anti-Experimental Liver Injury

ObjectiveTo study the effect of anti-HBV and the curative effect of anti-experimentalliver injury and anti-lipid peroxidation of the compoud of QING GAN PAI DUYIN (QGPDY) decoction. Wo expect anti-HBV and restraining experimental liverinjury mechanism and target of QGPDY decoction in the future, And providingscientific gist to the widely use of QGPDY in the clinic.Experimental contents1. Mice acute toxicity test of QGPDY.We recorded the toxicity appearance and dead condition, determined differentdensity of QGPDY on mice by observation of the experiment to decide adoptivedosage range in experiments. The results that QGPDY decoction 80g/kg/d maybe more effects on mice, but the dose of 40g/kg/d maybe had less effects onmice. So wo use the dosage all below 40g/kg/d in the following experiments.2. In-vivo and In-vivo experimental study of the anti-HBV effect of QGPDY.In vivo, ducking hepatitis B virus was used as animal model. The serum wascollected by the time points of T₀,T₅,T₁₀and P₃in accordance with the timepoint of drug intragastric administration. The quantity of DHBV in thesespecimens was evaluated by dot-blot assay. In conclusion, QGPDY could inhibitvirus replication rapidly, but no significant difference comparing with groupACV. there was no rebound phenomenon appearing in QGPDY after stoppingmedication.In-vivo, the2.2.15cell line was used as cell model. QGPDY was diluted intolldosage groups. The HBsAg and HBeAg in the supernatant were tested by ELISAassay. The cytotoxic of drug to the cell was evaluated by the MTT assay. TheTC₅₀, of QGPDY to 2.2.15 cell line was＞40.23mg/mL, the IC₅₀ of QGPDY to HBsAg,HBeAg was＜27.75mg/mL and 54.42mg/mL respectively, the TI of QGPDY was ＞1.45and＞0.74. It is the results that QGPDY had no direct repression on the2.2.15 cell In-vivo.3. immunity and chemistry experimental study of the anti-liver injury effectof QGPDY.In the experimental study of the anti-liver injury In vivo, animal model ofacute liver injury in mice included by concanavalin A was used for studyingthe therapeutic effects of QGPDY with high and low dosage groups (40g/kg,20g/kg, bifendate as the positive control. Activities of serumtransaminase, tumor necrosis factor-α(TNF-α) and immunoreactive fibronecti—γ(IFN-γ)in liver tissue was determined, and hepatic histopathologicalchange were observed.The results that ALT activity,IFN-γand TNF-αcontentin the high group of QGPDY were obviously lower than that of model group(P＜0.05), but no significant difference comparing with bifendate group(P＞0.05), hepatic histopathological change were alleviated in both QGPDY withhigh group and group bifendate. The experiment indicated QGPDY has a goodprotective effect on liver injury in mice induced by Con A by suppressing theactivation of the T-lymphocytes and reducing the release of IFN-γand TNF-α.In the experimental study of the anti-liver injury In vivo, animal model ofacute liver injury in mice included by Para was used for studying thetherapeutic effects of QGPDY with high, middle and low dosage groups(80g/kg, 40g/kg and 20g/kg), and bifendate as the positive control. Activitiesof serum transaminase,superoxide dismutase (SOD) and glutathionehormone(GSH)in liver tissue were determined, and hepatic histopathologicalchange were observed.The results that high group of QGPDY could significantlydepress the level of ALT, heighten the level of SOD and GSH, were obviouslylower to that of model group (P＜0.05), but no significant difference comparingwith bifendate group (P＞0.05), hepatic histopathological change werealleviated in both QGPDY with high group and group bifendate. The experimentindicated QGPDY has a good protective effect on liver injury in mice inducedby Para, its therapeutic mechanism is related to the antioxidation.ConclusionAbove the findings it confirmed that compound QGPDY has the good applicationprospect in anti-hepatitis B virus and anti-hepatic injury, it proved thepharmacology proof of QGPDY be utilized in clinical treatment.